Core Viewpoint - Beijing Strong Biotechnologies, Inc. (referred to as "the Company") has issued convertible bonds to raise funds for its diversified and high-quality in vitro diagnostic testing platform, with a total fundraising amount of RMB 1.139 billion [3][16]. Section 1: Bond Issuance Details - The Company approved the issuance of convertible bonds on September 6, 2021, and received regulatory approval from the China Securities Regulatory Commission on June 6, 2022 [2][3]. - A total of 11.39 million convertible bonds were issued at a face value of RMB 100 each, raising a gross amount of RMB 113.9 million, with a net amount of RMB 112.685 million after deducting issuance costs [3][4]. Section 2: Financial Performance - For the fiscal year 2024, the Company reported a revenue of RMB 165,893.20 million, a decrease of 4.75% compared to RMB 174,162.67 million in 2023 [21]. - The net profit attributable to shareholders increased by 1.70% to RMB 53,263.53 million from RMB 52,374.28 million in the previous year [22]. - The total assets of the Company grew by 7.71% to RMB 557,496.52 million, while the net assets attributable to shareholders increased by 11.11% to RMB 413,837.41 million [22]. Section 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various projects, with a total planned investment of RMB 128.9 million [16][18]. - The Company will self-finance any shortfall if the actual net proceeds are less than the planned investment amount [19]. Section 4: Bondholder Rights and Management - The bondholders have rights to interest payments, conversion to shares, and the ability to sell back their bonds under certain conditions [15][12]. - The Company has established a special account for managing the proceeds from the bond issuance, ensuring that funds are used as intended [23]. Section 5: Credit Rating - The Company has maintained a credit rating of AA- with a stable outlook from Zhongjian Pengyuan Credit Rating Co., Ltd. since November 2021 [20][27].